See the DrugPatentWatch profile for bosentan

Based on the information available, pregnancy is considered a reason to stop bosentan use. Bosentan is a medication used to treat pulmonary arterial hypertension, and it belongs to a class of drugs called endothelin receptor antagonists [1]. According to the prescribing information, bosentan can cause serious birth defects, and therefore, it is contraindicated in women who are pregnant or planning to become pregnant [2].

Furthermore, the manufacturer of bosentan, Actelion Pharmaceuticals, recommends that women of childbearing potential should use effective contraception during treatment with bosentan and for at least one month after stopping the medication [3]. Additionally, women who become pregnant while taking bosentan should immediately inform their healthcare provider [3].

It is important to note that the risk of birth defects associated with bosentan use is significant, and therefore, it is crucial to follow the prescribing information carefully [2]. Women who are considering becoming pregnant or who are pregnant and taking bosentan should consult their healthcare provider to discuss the risks and benefits of continuing the medication [3].

In summary, based on the available information, pregnancy is a reason to stop bosentan use due to the risk of serious birth defects. Women who are taking bosentan and are considering becoming pregnant should consult their healthcare provider to discuss the risks and benefits of continuing the medication.

Sources:

1. DrugPatentWatch.com. Bosentan. <https://www.drugpatentwatch.com/drugs/bosentan>.
2. Tracleer (bosentan) tablets, for oral use. Full Prescribing Information. Actelion Pharmaceuticals US, Inc. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021357s023s024s025s026lbl.pdf>.
3. Tracleer (bosentan) tablets, for oral use. Medication Guide. Actelion Pharmaceuticals US, Inc. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021357s023s024s025s026medguide.pdf>.